Home › Trial NCT06894693
A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies
- Trial IDNCT06894693
- StatusNot Yet Recruiting
- PhasePhase 1
- Study typeInterventional
- SponsorGuangdong Ruishun Biotech Co., Ltd
- Enrollment13
- Start date2025-04-01
- ConditionsB-cell Non-Hodgkin's Lymphoma · Acute Lymphoblastic Leukemia
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.